MaxCyte, Inc. (NASDAQ:MXCT) CEO Maher Masoud Buys 75,000 Shares

Key Points

• CEO Maher Masoud of MaxCyte, Inc. purchased 75,000 shares at an average cost of $1.37 per share, totaling approximately $102,750, increasing his ownership to 175,000 shares.
• MaxCyte's stock recently saw an 8.7% increase, trading at $1.38, while the company has reported a negative EPS of ($0.12) for the last quarter.
• Multiple institutional investors have increased their stakes in MaxCyte, raising institutional ownership to 68.81% of the company's stock.

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CEO Maher Masoud acquired 75,000 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were acquired at an average cost of $1.37 per share, for a total transaction of $102,750.00. Following the completion of the transaction, the chief executive officer directly owned 175,000 shares of the company's stock, valued at $239,750. The trade was a 75.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

MaxCyte Trading Up 8.7%

NASDAQ:MXCT traded up $0.11 on Wednesday, hitting $1.38. The stock had a trading volume of 2,119,726 shares, compared to its average volume of 693,983. The business's 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $2.76. MaxCyte, Inc. has a 52-week low of $1.26 and a 52-week high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. The company had revenue of $8.51 million during the quarter, compared to the consensus estimate of $9.57 million. Analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Cadian Capital Management LP raised its stake in shares of MaxCyte by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company's stock worth $38,873,000 after buying an additional 1,155,476 shares during the period. Mirabella Financial Services LLP raised its stake in shares of MaxCyte by 78.4% in the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company's stock worth $14,388,000 after buying an additional 2,900,000 shares during the period. Mudita Advisors LLP raised its stake in shares of MaxCyte by 3.3% in the first quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock worth $9,087,000 after buying an additional 105,034 shares during the period. Chevy Chase Trust Holdings LLC raised its stake in shares of MaxCyte by 66.5% in the first quarter. Chevy Chase Trust Holdings LLC now owns 2,230,182 shares of the company's stock worth $6,088,000 after buying an additional 890,353 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of MaxCyte by 15.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,429,071 shares of the company's stock worth $5,945,000 after buying an additional 191,088 shares during the period. Institutional investors own 68.81% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stephens assumed coverage on MaxCyte in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $6.00 price objective on the stock. William Blair cut MaxCyte from an "outperform" rating to a "market perform" rating in a research report on Thursday, August 7th. BTIG Research reissued a "neutral" rating on shares of MaxCyte in a research report on Monday. Finally, Wall Street Zen cut MaxCyte from a "hold" rating to a "sell" rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.00.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.